Cellectis Overview
Company Headquarters: France, Paris
Founded: 1999
Workforce: ~161
Company Working: Cellectis is a clinical stage biotechnological company involved in the development of immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company operates through two segments—Therapeutics and Plants. Cellectis is currently developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL), UCART22 to treat ALL and non-Hodgkin lymphoma (NHL), ALLO-501 for treating relapsed/refractory NHL, and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm, among others
Strategy
Cellectis focuses on developing a diversified product portfolio by the innovation and development of products, thus delivering integrated solutions to large healthcare customers. It also emphasizes acquisitions and collaborations with players from the research background as well as contract manufacturing to enhance its presence in the industry.
